Start up investing the biotech sector continues to

The biotech sector continues to dominate start up investing metrics, with gene therapy and CRISPR R&D companies attracting record Series B valuations. Public market comparables forecast revenue CAGR above 30% through Africa and Asia will be the primary drivers of population growth globally in the next few decades. Funding these startups could also be a lucrative long-term bet considering the potential future size of these markets. “This is the age of AI — the big bang of a new industrial revolution,” said Jensen Huang, founder and CEO of NVIDIA. “The United Kingdom is in a Goldilocks moment, where world-class universities, bold startups, leading researchers and cutting-edge supercomputing converge. There has never been a better time to invest in the U.K. — AI is unlocking new science and sparking entirely new industries. With new capital and advanced infrastructure, we are doubling down to empower the U.K. to lead the next wave of AI innovation.” Start up investing in robotics is gaining momentum, particularly in manufacturing automation. Equity research points to a 40% expected rise in adoption rates through 2025, influencing bullish sentiment in small-cap industrial stocks.